260sek
-3,7 %
Date:2025-05-15Time:11:32:45Latest report:Q2-2025List:First NorthTicker:NEWBRY
Market Cap:69 msekEnterprise Value:56 msekNet Sales:41,5 msekEarnings:-13,4 msekEmployees:0ISIN:SE0015244884

Ratios

10-year key figure history for Newbury Pharmaceuticals turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Newbury Pharmaceuticals with index and moving average MA50 and MA200.

Stockprice:2,60
MA50:3,23
MA200:3,45
Price/MA200:-24,7 %
RSI (14):28,5
Price/MA50:-19,6 %

Description

Newbury Pharmaceuticals is a pharmaceutical company. The company develops a pipeline of in-house developed and licensed products with a focus on specialty drugs in areas such as oncology, rare diseases, and neurology. The company conducts its business within the Scandinavian market. Newbury Pharmaceuticals was founded in 2020 and has its headquarters in Lund.

Pharmaceuticals